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Tobacco smoking causes millions of cancer deaths annually. Tobacco smoke is a complex
mixture of thousands of chemicals including many known animal carcinogens. Because many
carcinogens form DNA adducts in target animal or human tissues, the detection of the formation
of adducts using such methods as postlabeling, immunoassay, fluorescence spectroscopy, and
mass spectrometry is a means of monitoring human exposure to tobacco carcinogens. Smokers
are at increased risk of cancer in many organs, and studies have revealed either specific adducts
related to smoking or increased levels of adducts in the lung, bronchus, larynx, bladder, cervix,
and oral mucosa of smokers. In a limited number of studies, the adducts and the carcinogens
responsible for them have been identified. Some studies have demonstrated higher levels of
adducts in the white blood cells of smokers, while other studies indicate other sources of
genotoxic agents, including diet, can contribute to the DNA damage observed in these cells.-
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Tobacco Use and
Tobacco-related Diseases
Tobacco smoking and related uses are a
major cause of human disease. Cigarette
smoking is causally related to cancer ofthe
respiratory tract, upper digestive tract, pan-
creas, renal pelvis, and bladder (1,2). Cigar
and pipe smoking are causally related to
cancer ofthe respiratory tract, oral cavity,
and esophagus. The use ofchewing tobacco
and oral snuff is associated with cancer of
the oral cavity, kidney, and bladder (3).
Passive smoking has also been widely
implicated as a risk factor for lung cancer
in nonsmokers. In addition to cancer,
smokers are at increased risk of stroke,
heart attack, peripheral vascular disease,
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aortic aneurysm, emphysema and bronchitis,
and, in old age, cataract and delayed bone
healing. Smoking also causes reduced fertil-
ity, excessive bleeding during pregnancy,
and lower infant birth weight (1).
Prior to the twentieth century, tobacco
use was largely confined to pipe and cigar
smoking among a small section ofthe pop-
ulation. The emergence oftobacco use as a
major cause of death and disease is the
result ofthe growth in popularity of ciga-
rettes, aided by the development of
machines for their mass production and
the invention ofsafety matches. Although
there has been a leveling, or even a decline,
in tobacco consumption in some Western
countries in the last few years, the global
trend is still one ofincreasing use. Cigarette
production worldwide is estimated to have
increased by 2.2% annually in the last 20
years, compared with an annual growth in
world population of 1.7%. It is predicted
that this trend will accelerate to 2.9% a
year throughout the 1990s (1).
Carcinogens in
Tobacco Smoke
Tobacco smoke is a very complex mixture
ofmaterials, containing around 400 to 500
gaseous components and 1 x 1010 parti-
cles/ml (4). More than 3,500 chemicals
make up the particulate phase and, overall,
at least 43 chemicals that have been
demonstrated to be animal carcinogens
have been detected in tobacco smoke. In
addition, tobacco smoke contains many
free radicals-those in the gaseous phase
being short-lived and those in the particu-
late phase relatively long-lived. In general,
sidestream smoke (also known as environ-
mental tobacco smoke, which is inhaled by
nonsmokers) contains higher levels of
identified carcinogens than mainstream
smoke (that which is directly inhaled by
smokers) (2).
Chemicals present in tobacco smoke
that are known to be carcinogenic to
animals belong to the following classes:
polycyclic aromatic hydrocarbons (PAHs),
aza-arenes, N-nitrosamines, aromatic
amines, heterocyclic amines, aldehydes,
inorganic compounds, and miscellaneous
organic chemicals (e.g., styrene, benzene,
and vinyl chloride) (2). Those for which
there is sufficient evidence ofcarcinogeni-
city in humans and which are listed as
Group 1 carcinogens by the International
Agency for Research on Cancer include
2-naphthylamine, 4-aminobiphenyl, ben-
zene, arsenic, chromium, and vinyl chlo-
ride. Other chemicals present that are
strongly suspected ofbeing human carcino-
gens are nickel, cadmium, acrylonitrile,
benzo[a]pyrene, and polonium-210.
The constituents of tobacco smoke
most likely to be responsible for tumor
initiation in different organs have been
deduced by consideration ofthe organotro-
pism observed in occupationally induced
cancers and also from the sites of tumor
formation in animal studies. Thus
Hoffmann and Hecht (4) propose that the
likely agents responsible for tobacco-related
lung and larynx cancer are PAHs, acetalde-
hyde, and formaldehyde (with polonium-
210 as a possible minor factor); bladder
cancer is attributable to aromatic amines;
cancers ofthe esophagus and pancreas are
attibutable to tobacco-specific nitrosa-
mines, while PAHs and nitrosamines are
implicated in cancer ofthe oral cavity.
The Detection and Biological
Significance of DNA Adducts
Many chemical carcinogens (and most
human carcinogens) exert their biological
effects through the covalent binding of
electrophilic species to cellular DNA to
form modified nucleotides known as
adducts. Thus examination of.human (or
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animal) DNA for the presence of DNA
adducts is a means ofdetecting prior expo-
sure to carcinogenic agents. Because DNA
is the critical target for carcinogenesis, the
formation ofa DNA adduct is an event of
potential biological significance. In theory,
the presence of adducts in an individual
indicates that the person is at risk ofdevel-
oping cancer, although the influence of
modulating factors on the carcinogenic
process will make it unlikely that the mag-
nitude ofthe risk can be calculated from a
single parameter such as the level of DNA
adducts. Ofmore immediate interest is the
possibility ofidentifying the agents present
in tobacco smoke that initiate cancer in
humans by characterizing the DNA
adducts formed in the tissues ofsmokers.
In recent years several sensitive methods
have been developed and widely used to
investigate this issue (5). Where identifi-
cation ofadducts has been achieved, it has
often been through the use of combina-
tions ofseveral methods. As these methods
have been described in considerable detail
elsewhere, the present discussion will be
confined to a few briefcomments.
Immunochemical methods, employing
antibodies raised against synthetic carcino-
gen-DNA adducts, have provided a sensi-
tive means ofdetecting adducts in human
tissues. Because many antibodies show a
degree of cross-reactivity with adducts
formed by different compounds of the
same chemical class (6), this allows the
general identification of adducts formed
by a class, but not by a specific chemical.
On the other hand, the cross-reactivity can
be exploited by using immunoaffinity
column chromatography to concentrate
adducts from human DNA for further
characterization.
An extremely versatile and sensitive
method of adduct detection is the 32P-
postlabeling assay (7). It can been applied
to the detection of many different chemi-
cally stable adducts, including those
formed by large aromatic carcinogens and
small aliphatic ones. The amount ofinfor-
mation concerning the structure of the
adduct is limited to its general chromato-
graphic characteristic, from which can be
inferred its apparent size, hydrophobicity,
and aromaticity. Also, as described below,
to some extent, the effect of variations
of the assay on adduct recovery can give
some information on the types ofadduct
being detected.
Although more selective and less sensi-
tive than these methods, fluorescence spec-
troscopy provides more information on the
identity ofadducts in human DNA. Clearly
it is applicable only to those adducts that
contain fluorescent carcinogen moieties,
and this has limited its use in practice to
identifying PAH-DNA adducts (8). Some
methylated nucleosides are also fluorescent,
but the sensitivity is often insufficient for
human biomonitoring studies.
The method with the greatest potential
for structural identification of DNA
adducts is mass spectrometry. There are a
number of cases where human carcino-
gen-DNA adducts have been characterized
by mass spectrometry (5), although its
wider application in human biomonitoring
has, to some extent, been hindered by the
availability of insufficient amounts of
DNA in which to identify the generally
low levels ofadducts present. Nevertheless,
improvements in sensitivity and sample
derivatization are anticipated in the near
future such that it will be possible to iden-
tify many more of the carcinogen-DNA
adducts that are undoubtedly present in
human tissues and are already detected by
immunochemical and postlabeling meth-
ods. Other physical methods applied to
carcinogen-DNA adduct detection include
electrochemical detection and atomic
absorption spectrometry (8).
Many studies of DNA adducts in
human tissues have been carried out using
these methods either singly or in combina-
tion. A number ofquestions are pertinent
to studies of DNA adduct determinations
in human tissues. First, what are the
adducts that are being detected in the
tissues? Second, with what efficiency are
they detected? Third, to what extent do
they present a true picture of the total
DNA damage?
In most cases, these questions have only
been partially answered; however, as dis-
cussed in the examples below, even the par-
tial information obtained has been useful.
As already stated, antibodies raised against
a particular DNA adduct cross-react with
other adducts ofthe same class, giving an
indication ofthe type ofadducts present in
a tissue when an antigenic response is
elicited. Also, the digestion, enhancement,
labeling, and chromatography procedures
used in 32P-postlabeling determine the type
of DNA adduct detected. For example,
very different chromatographic procedures
are used to resolve adducts formed by
bulky aromatic carcinogens and those
formed by simple alkylating agents.
Although 32P-postlabeling does not pro-
vide a direct means ofidentifying the DNA
binding species detected, adducts can also
be characterized to a limited extent by
comparison of their chromatographic
mobilities with those ofcharacterized stan-
dards (when available) and by determining
the effects ofdifferent enhancement proce-
dures on the quantity and quality of the
adducts recovered. For example, the nucle-
ase P1 digestion method of sensitivity
enhancement is suitable for PAH-DNA
adducts but not aromatic amine adducts,
whereas the butanol extraction method is
suitable for both classes. However, neither
method would be expected to detect the
more polar adducts formed by tobacco-
specific nitrosamines. Without synthetic
standards for all the adducts detected, the
efficiency oftheir recovery by postlabeling
or their reactivity toward the antibodies
used cannot be determined so that adduct
levels may be underestimated; this possibil-
ity is widely recognized. To some extent,
these shortcomings will be addressed as
more complete characterization ofadducts
is achieved.
Because of the unequivocal epidemio-
logical evidence that tobacco smoking
causes cancer in a number of human
tissues, monitoring DNA for the presence
ofsmoking-related adducts by comparing
samples from smokers and nonsmokers
provides a means ofvalidating the detection
methods that have been described. In addi-
tion, identification ofthe adducts formed
in different tissues will provide clues to dis-
tinguish the biologically important compo-
nents oftobacco smoke that are responsible
for tumor initiation in different tissues.
Smoking-related DNA
Adducts in Human Tissues
There have been several 32P-postlabeling
studies of DNA adducts in lung tissue. A
consistent finding is that levels ofaromatic
and hydrophobic adducts are significantly
higher in smokers than in nonsmokers
(9-13). In some studies, a linear correlation
between estimated total or daily tobacco
smoke exposure and adduct levels has been
observed. However, in other studies, this
correlation has not been seen. One prob-
lem with these analyses is the inevitable
uncertainty regarding the accuracy ofself-
reporting ofsmoking habits by the subjects
in the study population. Another study has
found that adduct levels, when adjusted
for total tobacco smoke exposure, are
higher in women's lungs than in men's
(14). Interestingly, there is some epidemio-
logical evidence to indicate a greater risk of
lung cancer for female smokers than for
male smokers (15,16).
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The pattern ofsmoking-related adducts
revealed by 32P-postlabeling consists of a
diagonal zone of radioactivity on the
2-dimensional thin-layer chromatograms
generated by resolution of the labeled
digests. This is widely thought to indicate
that a complex mixture of adducts results
from exposure of the respiratory tract to
tobacco smoke. The fact that similar levels
of adducts are detected in lung tissue by
both the butanol extraction and nuclease
P1 digestion procedures is an indication
that PAHs are the major class of carcino-
gens responsible for the damage detected
(11). This is supported by the detection of
adducts in human lung DNA by immuno-
assay using antibodies that recognize PAH-
DNA adducts (17). Furthermore, fluores-
cence spectral analysis ofhuman lung DNA
has demonstrated the presence of adducts
formed by benzo[a]pyrene (18-20).
Other studies have demonstrated the
presence of other, apparently smoking-
related, adducts in human lung tissue.
Foiles et al. (21,22) have identified by mass
spectrometry the formation of4-hydroxyl-
1-(3-pyridyl)-1-butanone in hydrolysates
ofhuman smokers' lung DNA; this prod-
uct results from the formation of DNA
adducts by the tobacco-specific nitrosamine
NNK [4-(N-methyl-N-nitrosamino) 1-
(3-pyridyl)-1-butanone]. Also, the analysis
of bronchial DNA for the presence of
7-methylguanine has demonstrated, using
32P-postlabeling, significantly higher levels
in smokers than in nonsmokers (23).
Cancer ofthe larynx is strongly associ-
ated with tobacco smoking, and two stud-
ies have demonstrated the presence of
DNA adducts in this tissue. Degawa et al.
(24) showed that aromatic adducts were
present in the laryngeal DNA from smok-
ers, but not nonsmokers, and that these
adducts could be detected by both the
nuclease P1 digestion and butanol extrac-
tion modifications of32P-postlabeling.
Szyfter et al. (25), using the nuclease P1
digestion procedure, demonstrated the
presence of aromatic adducts in both
tumor and nontumor larynx tissue, but the
study population contained insufficient
numbers of nonsmokers for an adequate
analysis of differences in adduct levels
between smokers and nonsmokers.
Studies on DNA adducts in oral
mucosal cells have been conducted on vari-
ous groups of tobacco users with various
32P-postlabeling procedures. Dunn and
Stich (26) used a procedure that involved
limiting concentrations of ATP and
detected adducts in cells from betel nut
chewers, Khaini tobacco chewers, and
inverted smokers and also in cells from
nonsmoking controls. One ofthe adducts
was at higher levels in some ofthe exposed
groups, while two adducts were at reduced
levels. Another study oftobacco smokers,
tobacco chewers, and tobacco non-users
found low levels of DNA adducts in oral
mucosal cells from all three groups using
the butanol extraction procedure of the
32P-postlabeling assay (27). None of the
adducts detected were found to be specifi-
cally associated with tobacco smoking or
chewing. Foiles et al. (28), using the same
methods, reported that adduct levels were
significantly higher in the exfoliated oral
mucosal cells ofsmokers than ofnonsmok-
ers, although they also found that the
adduct patterns ofsmokers and nonsmok-
ers were qualitatively similar. In another
study in which both butanol extraction and
nuclease P1 digestion methods were used,
higher levels ofadducts were detected by
the former method, suggesting a significant
contribution of aromatic amines and/or
nitroaromatic compounds to DNA bind-
ing (29); this study also found that the
adduct levels were significantly higher
in smokers.
Another tissue in which higher levels of
adducts are detected by the butanol extrac-
tion procedure than by the nuclease P1
digestion method is the bladder (30-32).
Both biopsy samples and exfoliated cells
recovered from urine have been found to
be suitable sources of DNA for such stud-
ies. Again, adduct levels have been found
to be higher in smokers than in nonsmok-
ers, consistent with the increased risk of
bladder cancer faced by smokers. The evi-
dence in favor of aromatic amines as the
major adduct-forming class ofcompounds
in this tissue is compatible with the finding
that occupational exposure to aromatic
amines has resulted in bladder cancer.
Furthermore, one ofthe adducts detected
in human bladder DNA has been found to
be chromatographically indistinguishable
from the major DNA adduct formed by
4-aminobiphenyl (31).
Smoking is a risk factor for cervical
cancer, although epidemiologists are still
divided on whether this association is real
or is due to a confounding factor (33).
Significantly higher levels ofDNAadducts,
detected by 32P-postlabeling, have been
found in the cervical epithelium ofsmokers
than of nonsmokers (34,35), an observa-
tion that gives some credence to the epi-
demiological observations, although it does
not prove a causal relationship. In these
studies significant differences in adduct
levels were observed when butanol extrac-
tion was used as the enrichment procedure,
but not when nuclease P1 digestion was
used (34,35). In another study where
nuclease P1 digestion was used to enhance
sensitivity, elevated adduct levels were
detected only in those smokers who were
also users of oral contraceptives (36). As
oral contraceptive use is another apparent
risk factor for cervical cancer, this is an
interesting observation that warrants fur-
ther investigation.
Several environmental carcinogens are
mammary carcinogens in experimental ani-
mals (37) and yet there is no clear evidence
for the involvement ofany such agent in
the etiology of human breast cancer.
Nevertheless, the pattern ofmutations seen
in the p53 gene in human breast tumors
suggests the involvement of exogenous
agents in inducing these mutations in a
significant proportion ofcases (38). Further-
more, there is a suggested association
between heavy smoking from an early age
and increased risk ofbreast cancer (39) and
also between passive smoking and breast
cancer (40). Both observations require
confirmation. A pilot postlabeling study of
DNA from breast tumor and adjacent nor-
mal tissue DNA found that an adduct pat-
tern showing the diagonal radioactive zone
characteristic ofsmoking-related adducts in
other tissues was present in 5 of 15 samples
from smokers but not in any of 8 samples
from nonsmokers (41). This was statisti-
cally significant (p< 0.01) although there
was no difference in the overall levels of
adducts in smokers and nonsmokers.
There are some epidemiological studies
[cited in (42)] that point to the increased
risk ofgastric cancer among male smokers.
In support of this evidence, DNA adduct
levels were found by 32P-postlabeling to be
significantly higher in gastric tumor tissue
from male smokers than in tissue from
nonsmokers (42).
For reasons that are not entirely clear,
cigarette smoking is a risk factor for anal
cancer (OR= 11.0; 95% CI 2.8-43.1 for
men who have smoked for 30 or more
years) (43). A pilot postlabeling study of
DNA from anal tissue of 10 smokers and
10 nonsmokers has demonstrated that
9 of 10 ofthe smokers' samples produced
the diagonal zone of radioactivity while
none of the nonsmokers' samples did
(P Skinner, A Hewer, and DH Phillips,
unpublished results).
Postlabeling analysis has been carried
out on human sperm DNA to determine
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whether smoking-related adducts are
formed in germ cells (44). No clear evi-
dence of differences in adduct patterns
among heavy smokers, light smokers, and
nonsmokers was observed. It remains the
case that there is no convincing evidence
that smoking induces germ-line mutations
in humans (45).
The studies described thus far have all
involved examination of DNA isolated
from target organs or from cells that are
perceived to be potential target cells. In
many cases, these samples are not readily
obtainable from healthy individuals and
require surgical or somewhat invasive
procedures that preclude, for practical or
ethical reasons, widespread population
sampling or repeated sampling ofthe same
individuals. Sources ofhuman DNA that
have been analyzed for adducts are listed
in Table 1. For studies ofoccupational or
environmental exposure to carcinogens
(where the study populations are healthy),
DNA from white blood cells is a readily
Table 1. Sources of DNA for human biomonitoring of
tobacco-related cancer.
Target
Source tissue Accessibilitya
Peripheral blood No High
lymphocytes
Buccal mucosa Yes High
Cervical epithelial cells Yes High
Exfoliated bladder cells Yes High
Hair roots No High
Sperm cells No High
Skin biopsies No Medium
Bladder biopsies Yes Medium
Lung washings or biopsies Yes Medium
Bone marrow cells No Medium
Placenta No Medium
Surgical specimens Yes Low
(varioustissues)
Postmortem tissue Yes Low
(varioustissues)
aPractical or ethical ease of obtaining material from
humans; consideration is also given to the possibility
of obtaining samples from the same individuals on
subsequent occasions.
obtainable source of DNA for analysis.
Many studies have demonstrated increased
levels ofadducts in leukocytes or lympho-
cytes as a result ofoccupational exposure to
carcinogens, in particular to PAHs (32).
Where investigators have compared smok-
ers and nonsmokers, however, results have
been variable. In studies ofwhole white
blood cells and some studies ofthe mono-
cyte and lymphocyte fraction (consisting
mostly of lymphocytes), adduct levels in
smokers and nonsmokers were the same
(11,46,47). In other studies on lympho-
cytes and monocytes, elevated levels in
smokers were detected (48,49). In one
study in which DNA from the lungs and
white blood cells of lung cancer patients
were analyzed, no correlation between
adduct levels in the two tissues was
observed (50). At the same time, studies of
occupational exposures to carcinogens that
have taken account of dietary influences
have demonstrated that putative ingestion
ofcarcinogens in food (e.g., in barbecued
meat) can result in detectable DNA
adducts in blood cells (51). Thus it is clear
from these studies that, while monitoring
white blood cells (or the mononuclear cell
fraction) for DNA adducts can in some
instances provide evidence ofexposure to
tobacco, the confounding influence of
genotoxic agents from other sources may
also be observed.
Holz et al. (52) have reported that
monocytes, but not unstimulated human
lymphocytes, formed DNA adducts when
treated separately with benzo[a]pyrene in
vitro, but that lymphocytes incubated in the
presence ofmonocytes did form adducts.
They concluded that lymphocytes in whole
blood form adducts from the carcinogen
after it has been activated byother cells.
Studies of 7-methylguanine levels
have demonstrated that they differ signi-
ficantly between lymphocytes and granu-
locytes (53). Also, the mean adduct
levels were higher in smokers than in
nonsmokers (p<0.05).
Finally, it is widely recognized that
tobacco smoking during pregnancy affects
the unborn child. Transplacental exposure
to tobacco carcinogens is demonstrated by
the detection in placental DNA ofadducts
derived from PAHs present in tobacco
smoke (54,55).
Summary and Conclusions
The majority of investigations on the pres-
ence of DNA adducts in the target tissues
ofsmokers either demonstrate the presence
ofsmoking-related adducts or indicate that
adduct levels are higher in smokers than in
nonsmokers, although some ofthe adducts
may be present in both groups. The pres-
ence ofadducts in nonsmokers may be the
result ofpassive smoking or ofexposure to
carcinogens from other environmental
sources. These results reinforce the view
that the carcinogenic effects of tobacco
smoke are a result ofthe genotoxic action
ofsome ofthe many carcinogens present in
this extremelycomplex mixture.
Although most ofthe adducts that have
been detected by methods such as post-
labeling and immunoassay have not been
fully characterized, some general conclu-
sions can be made about their probable
nature. Thus, most of bulky adducts
detected in the respiratory tract appear to
be formed by PAHs while the predominant
damage in the urinary bladder probably
derives from aromatic amines. Other stud-
ies have indicated adduct formation in the
lung by nitrosamines, but the extent of
damage relative to that caused by PAHs
has not yet been determined. The presence
ofadducts formed by benzo[a]pyrene and
NNK in lung tissue and by 4-amino-
biphenyl in bladder cells has been demon-
strated with reasonable certainty; it is
anticipated that recent advances in the
methodology for adduct detection and
characterization will result in rapid
progress in identifying many more of the
adducts present in human DNA in the
near future.
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